# Patricia Pautier

Source: https://onco.cc/people/patricia-pautier/  
OnCo record `patricia-pautier` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Paris oncologist who led LMS-04, the trial that showed doxorubicin plus trabectedin lengthens survival in advanced leiomyosarcoma compared with doxorubicin alone.

## Summary

Patricia Pautier is a medical oncologist at Gustave Roussy who treats sarcomas and gynaecological cancers. She was first author of the 2022 Lancet Oncology report of the French Sarcoma Group LMS-04 trial, in which doxorubicin plus trabectedin followed by trabectedin maintenance improved progression-free survival compared with doxorubicin alone as first-line treatment for metastatic or unresectable leiomyosarcoma; the 2024 update showed an overall survival gain.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: sarcoma; trialist
- Role: Medical oncologist, Gustave Roussy
- Specialisms: Leiomyosarcoma; Gynaecological sarcomas; Ovarian cancer

## Connected records

- cancers: [Leiomyosarcoma](https://onco.cc/cancers/leiomyosarcoma/), [Retroperitoneal sarcoma](https://onco.cc/cancers/retroperitoneal-sarcoma/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/), [Soft tissue sarcoma of the extremity (localised and advanced)](https://onco.cc/cancers/extremity-soft-tissue-sarcoma/)
- institutions: [Gustave Roussy](https://onco.cc/institutions/gustave-roussy/)
- key papers: [LMS-04: doxorubicin plus trabectedin followed by trabectedin maintenance versus doxorubicin alone in metastatic leiomyosarcoma](https://onco.cc/key-papers/paper-lms-04-doxorubicin-trabectedin-lancet-oncol-2022/)

---
JSON: https://onco.cc/api/v1/entities/patricia-pautier.json